Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years
You may also be interested in...
Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 2 of 2)
Pfizer Inc.'s Rod MacKenzie, senior VP and Head of Worldwide PharmaTherapeutics Research talked with PharmAsia News about the evolution of Pfizer's virtual R&D approach in China and larger Asia. Pfizer announced last week that it would be opening a new R&D center for antibacterials in Shanghai after closing its antibacterial R&D plant in Groton, Conn. The move marks the first dedicated R&D unit for a specific therapy area in Asia.
Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 2 of 2)
Pfizer Inc.'s Rod MacKenzie, senior VP and Head of Worldwide PharmaTherapeutics Research talked with PharmAsia News about the evolution of Pfizer's virtual R&D approach in China and larger Asia. Pfizer announced last week that it would be opening a new R&D center for antibacterials in Shanghai after closing its antibacterial R&D plant in Groton, Conn. The move marks the first dedicated R&D unit for a specific therapy area in Asia.
Translational R&D Models Like Precompetitive Alliances Needed To Energize Drug Discovery - Indian Symposium
AHMEDABAD, India - Precompetitive collaborations between pharmaceutical companies mainly aimed at identifying biomarkers should intensify further to help weed out undesirable molecules in trials sooner than in expensive Phase II or III studies. Industry-academia alliances are increasingly gravitating in the same direction